1-3 of 3
Sahra Ali, FRCPath, FRCP, BM, MRCP
Close
Sort by
Journal Articles

Response To Ruxolitinib In Patients With Intermediate-1, Intermediate-2 and High-Risk Myelofibrosis: Interim Results Of The UK Robust Trial

Claire N Harrison, DM, FRCP, FRCPath, Richard E Clark, MD, Joseph Chacko, Steven Knapper, DM BMBCh, John Yin, MD, Dragana Milojkovic, PhD, Mira Farquharson, FRCPath, MBChB, MRCP, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Mamta K Garg, MD, FRCP, FRCPath, Christopher Andrews, PhD, Cstat, CSci, Susan M Graham, PhD, Adam J. Mead, M.D., Ph.D.
Journal: Blood
Blood (2013) 122 (21): 2826.
https://doi.org/10.1182/blood.V122.21.2826.2826
Published: 2013
Journal Articles

A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML

Alan K Burnett, MD, ChB, FRCP, FRCPath, FMedSci, Nigel H. Russell, MD, Mary Frances McMullin, MD, Jonathan Kell, MD, MB, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Paul Moreton, Andrew H Wei, MBBS, PhD, Lars Kjeldsen, MD, PhD, Robert K. Hills, MA, MSc, DPhil
Journal: Blood
Blood (2012) 120 (21): 889.
https://doi.org/10.1182/blood.V120.21.889.889
Published: 2012
Journal Articles

The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial

Alan K Burnett, MD, Robert K Hills, MA, MSc, DPhil, Ann E. Hunter, MBBS, FRCP, FRCPath, Donald Milligan, MD, MBChB, William J. Kell, MD, MB, Keith Wheatley, John L Yin, MD, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Lars Kjeldsen, MD, PhD, David Bowen, Nigel H. Russell, MD
Journal: Blood
Blood (2011) 118 (21): 582.
https://doi.org/10.1182/blood.V118.21.582.582
Published: 2011